MENU

Sirtex Medical soars 7% on Macquarie upgrade

Sirtex Medical (ASX: SRX), a biotech company that specialises in liver cancer treatments, jumped 7% higher to around $11 on Thursday after an upgrade from Macquarie.

“Macquarie rates SIRTEX MEDICAL as Outperform, with a price target of $14.30. Macquarie is very confident about the growth prospects for this company, not just in terms of market conditions but also clinical outcomes, new avenues for growth and the strategic direction.”

Sirtex shares have jumped 113% over the past year on the back of strong dose sales of its SIR-Spheres microspheres targeted radioactive liver cancer treatment. Although trading at a premium valuation, the future continues to look bright for Sirtex.

If you are looking for the next small cap stock to rocket higher, The Motley Fool’s FREE report titled Two Small Cap Superstars could be just for you. Click here now to access this free brand-new research report, including names, codes, and all the details of the two “superstars.”

More reading

The Motley Fool’s purpose is to help the world invest, better.  Click here now  for your free subscription to Take Stock, The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.  This article contains general investment advice only (under AFSL 400691). Motley Fool General Manager Bruce Jackson doesn’t own shares in any companies mentioned in this article.

 

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!